We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion (UGE). This was a single-arm multicenter prospective study. A total of 92 people with T2DM aged 20 to 70 years with glycosylated hemoglobin (HbA1c) levels ≥7.0% and ≤9.5% were enrolled. Ipragliflozin (50 mg) was added to the background therapy for these people for 12 weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were decreased from 7.6% to 6.9% and 62.0% of the people reached the HbA1c target of less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lipid parameters were improved after ipragliflozin treatment (all P<0.001). The baseline HbA1c (r=0.66, P<0.001) and morning spot urine glucose to creatinine ratio (r=−0.30, P=0.001) were independently associated with the HbA1c reduction. Ipragliflozin treatment for 12 weeks improves glycemic control and other metabolic parameters. A higher HbA1c and lower UGE at baseline predicts a better glucose-lowering efficacy of ipragliflozin.

Citations

Citations to this article as recorded by  

• Preventing and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 2 Diabetes: Promising Therapeutic Agents and Strategies
  Allison Zhang, Rita El Hachem, Jennifer Goldman
  ADCES in Practice.2024; 12(1): 38.     CrossRef
• Association of common variant rs9934336 of SLC5A2 (SGLT2) gene with SARS-CoV-2 infection and mortality
  Anamika Das, Gunanidhi Dhangadamajhi
  Egyptian Journal of Medical Human Genetics.2024;[Epub]     CrossRef
• Mathematical Models of the Effect of Glucagon on Glycemia in Individuals With Type 2 Diabetes Treated With Dapagliflozin
  Tomoko Yamada, Hikaru Sugimoto, Ken-ichi Hironaka, Yasuko Morita, Hiroshi Miura, Natsu Otowa-Suematsu, Yuko Okada, Yushi Hirota, Kazuhiko Sakaguchi, Shinya Kuroda, Wataru Ogawa
  Journal of the Endocrine Society.2024;[Epub]     CrossRef
• β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 6 months
  Minyoung Lee, Yongin Cho, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-Wan Lee
  Diabetes & Metabolism.2023; 49(4): 101427.     CrossRef
• A Comparative Study on the Efficacy and Safety of Dose Escalation of Luseogliflozin in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control
  Tadashi Arao, Yosuke Okada, Akira Kurozumi, Yoshiya Tanaka
  Cureus.2023;[Epub]     CrossRef
• Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitors response
  Bo Xu, Shaoqian Li, Bo Kang, Shangzhi Fan, Canyu Chen, Weiyi Li, Jixiang Chen, Zunbo He, Fan Tang, Jiecan Zhou
  Molecular Biology Reports.2023; 50(11): 9637.     CrossRef
• Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level
  Sjoukje van der Hoek, Jasper Stevens
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus
  Keisuke Monobe, Shinsuke Noso, Naru Babaya, Yoshihisa Hiromine, Yasunori Taketomo, Fumimaru Niwano, Sawa Yoshida, Sara Yasutake, Tatsuro Minohara, Yumiko Kawabata, Hiroshi Ikegami
  Journal of Diabetes Investigation.2021; 12(5): 728.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef